A receptor may recognize more than one related peptide. Target-selection evidence needs to address recognition of healthy tissue as well as the intended target.
A primary investigation of an affinity-enhanced MAGE-A3-directed receptor identified cross-recognition of a peptide from titin after unexpected cardiac toxicity. This was a particular engineered-receptor program, not a toxicity rate for all T-cell therapies or neoantigen vaccines. It illustrates why target-gene expression and a sequence match alone are insufficient descriptions of receptor specificity. Proposed-target recognition and off-target recognition need evidence in relevant systems.
Shares Peptide binding, presentation and immune recognition, Immune measurements and product evidence, Neoantigen.
Shares Peptide binding, presentation and immune recognition, Immune measurements and product evidence, Antigen presentation & immune editing.
Shares Peptide binding, presentation and immune recognition, Immune measurements and product evidence, Neoantigen, Antigen presentation & immune editing.
Shares Peptide binding, presentation and immune recognition, Immune measurements and product evidence, Neoantigen, Antigen presentation & immune editing.
Shares Binder affinity, epitope and developability, Immune measurements and product evidence.
Shares Peptide binding, presentation and immune recognition, Immune measurements and product evidence.
Shares Peptide binding, presentation and immune recognition, Immune measurements and product evidence.
Shares Binder affinity, epitope and developability, Immune measurements and product evidence.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/